LipoVation
Preclinical biotechnology company developing lipid- and nanoparticle-based delivery systems for systemic therapeutics and for vaccine antigen delivery. Pipeline includes reformulation of topical antibiotics for systemic use, lipid-based protein antigen vaccine platforms, and tumor-targeted nanoparticle adjuvants. Activities span preclinical studies through IND-enabling and early clinical development. The company completed a strategic acquisition to expand liposome and nanoparticle capabilities.
Industries
Nr. of Employees
small (1-50)
LipoVation
Products
Injectable liposomal reformulation of mupirocin
Liposomal injectable formulation of mupirocin intended to enable systemic administration and enhanced delivery to inflamed or infected tissues.
Nanoparticle-encapsulated angiotensin receptor blocker for tumor targeting
Nanoparticle formulation of an angiotensin receptor blocker intended as a tumor-targeted adjuvant to immunotherapies and chemotherapies to modulate the tumor microenvironment.
Lipid-based protein antigen vaccine platform
Lipid assembly platform for protein antigen delivery intended to improve antigen presentation and immune response durability for emerging infectious disease targets.
Injectable liposomal reformulation of mupirocin
Liposomal injectable formulation of mupirocin intended to enable systemic administration and enhanced delivery to inflamed or infected tissues.
Nanoparticle-encapsulated angiotensin receptor blocker for tumor targeting
Nanoparticle formulation of an angiotensin receptor blocker intended as a tumor-targeted adjuvant to immunotherapies and chemotherapies to modulate the tumor microenvironment.
Lipid-based protein antigen vaccine platform
Lipid assembly platform for protein antigen delivery intended to improve antigen presentation and immune response durability for emerging infectious disease targets.
Services
Internal R&D advancing liposomal reformulations, nanoparticle constructs, and lipid-based vaccine candidates through preclinical efficacy testing and IND-enabling activities.
CMC strategy development and coordination with contract development and manufacturing organizations to produce GMP clinical batches for regulatory submissions and first-in-human studies.
Internal R&D advancing liposomal reformulations, nanoparticle constructs, and lipid-based vaccine candidates through preclinical efficacy testing and IND-enabling activities.
CMC strategy development and coordination with contract development and manufacturing organizations to produce GMP clinical batches for regulatory submissions and first-in-human studies.
Expertise Areas
- Liposomal and nanoparticle drug formulation
- Drug-loading and controlled-release optimization for lipid carriers
- Lipid-based vaccine antigen delivery
- Preclinical efficacy and microbiological susceptibility testing
Key Technologies
- Liposomal drug delivery
- Nanoparticle drug delivery
- Remote drug-loading methods
- Controlled-release lipid systems
News & Updates
Press release describing regulatory and manufacturing progress for a liposomal systemic formulation of mupirocin, submission of a clinical trial application, and collaboration with a CDMO for GMP clinical-batch production.
Press release announcing completion of a strategic acquisition of a lipid/nanoparticle technology company to expand nanoparticle-based drug development capabilities and platforms.
Company annual report filed on OTC Markets.
Quarterly financial report available via OTC Markets.
Quarterly financial report available via OTC Markets.
Quarterly financial report available via OTC Markets.
Press release describing regulatory and manufacturing progress for a liposomal systemic formulation of mupirocin, submission of a clinical trial application, and collaboration with a CDMO for GMP clinical-batch production.
Press release announcing completion of a strategic acquisition of a lipid/nanoparticle technology company to expand nanoparticle-based drug development capabilities and platforms.
Company annual report filed on OTC Markets.
Quarterly financial report available via OTC Markets.
Quarterly financial report available via OTC Markets.
Quarterly financial report available via OTC Markets.